Enterprise Value
0.00
Cash
52.2M
Avg Qtr Burn
N/A
Short % of Float
7.22%
Insider Ownership
10.26%
Institutional Own.
90.41%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BLU-5937 (P2X3 antagonist) Details Chronic pruritus, Atopic pruritus | Failed Discontinued |